Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):137–9.
Gross SW. Sarcoma of the long bones; based upon a study of one hundred and sixty-five cases. Clin Orthop Relat Res. 1975;438(156):5.
Cortes EP, Holland JF, Wang JJ, Glidewell O. Adriamycin and amputation in primary osteogenic sarcoma. Proc Am Assoc Cancer Res Ann Meeting. 1974;15(3):170.
Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Murphy ML. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 2015;33(4):1151–63.
Faisham WI, Mat Saad AZ, Alsaigh LN, Nor Azman MZ, Kamarul Imran M, Biswal BM. Prognostic factors and survival rate of osteosarcoma: a single-institution study. Asia-Pac J Clin Oncol. 2017;13(2):e104–10.
National Comprehensive Cancer Network. Bone Cancer (Version 1.2018). Accessed 29 Aug 2017.
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C. Pretreatment neutrophil-to lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16(1):320.
Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J Surg Oncol. 2008;97(5):456–61.
De Vries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:958–65.
Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40.
Dolan RD, McSorley ST, Horgan PG, Laird B, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134–46.
Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–10.
Mclaren PJ, Bronson NW, Hart KD, Vaccaro GM, Gatter KM, Thomas CR. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can predict treatment response to neoadjuvant therapy in esophageal cancer. J Gastrointest Surg. 2017;21(4):607–13.
Yong-Jiang L, Kai Y, Min-Xun L, Wen-Biao Z, Cong X, Chong-Qi T. Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma. Onco Targets Ther. 2017;10:5255–61.
Bangjian L, Yujing H, Yuanjue S, Jianjun Z, Yang Y, Zan S, et al. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016;6:39862.
Enneking WF. Musculoskeletal tumor surgery. New York: Churchil Livingstone, Inc; 1983.
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4.
Kim TG, Park W, Kim H. Baseline neutrophil–Lym- phocyte ratio and platelet–lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori. 2018;105(5):434-40.
Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 2014;14:94.
Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lympho- cyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107:695–9.
Shen L, Zhang H, Liang L, Li G, Fan M, Wu Y. Baseline neutrophil- lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295.
Chae S, Kang KM, Kim HJ, Kang E, Park SY, Kim JH. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer. Curr Oncol. 2018;25(2):e113.
Liu K, Zhao L, Wang ES. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. Pathol Res Pract. 2018;214(8):1074-80.
Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008;18(1):3–10.
Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Medica. 2014;57(2):65–72.
Grivennikov SI, Kuprash DV, Liu ZG, Nedospasov SA. Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: from simple paradigms to complex mechanisms. Int Rev Cytol. 2006;252(undefined):129–61.
De Larco JE, Wuertz BRK, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10(15):4895–900.
Müller I, Munder M, Kropf P. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 2009;30(11):522–30.
Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60.
Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23(3):141–8.
Ownby HE. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. Cancer. 1983;52(1):126-30.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.